Developing a green synthesis process for a growth promoter drug for animals
Learn how Syngene developed a green synthesis process for a growth promoter drug for an animal health company that reduced the cE factor and PMI value by 80% while achieving high yield and cost-efficiency.
Reducing variability in gene expression: Bottlenecks and Solutions
Explore challenges in reducing the variability in gene expression in traditional cell line development (CLD) and the power of the transposon system to address these inefficiencies.
Enabling a four-fold increase in titer for mAb manufacturing using Syngene’s platform process
Learn how Syngene’s platform approach to mAb manufacturing helped a biopharma company achieve a four-fold increase in titer in less than a year, resulting in improved efficiency and reduced costs.
IND-enabling safety tox studies for FDA submission in just 9 months
Learn how Syngene supported a pharma company in completing IND-enabling safety tox studies for their lead compound for treating painful neuropathies in less than nine months.
Developing a unique hybridoma platform for manufacturing mAb cocktail formulations
Learn how Syngene developed a unique hybridoma platform for manufacturing mAb cocktail formulations for use in reagent kits designed to activate and expand human T cells for immunotherapy in patients.
Harnessing the immune system for cancer cell-therapy
Explore the top challenges in developing CAR-T therapy for treating cancer and how leading CRO-CDMO Syngene supports clients in bringing this therapy to patients faster.
Development of a Scalable Process for the Synthesis of Cyclopropyl-Methyl-Proline with Complex Stereochemistry: A Key Building Block of Factor D Inhibitors
Publication: ACS Publications
Quantifying a biomarker in mice brain for treating mood and anxiety disorders
A robust LC-MS-based quantitative method developed at Syngene to measure biomarker 2-AG in mice brain tissues for treating mood and anxiety disorders.
SynWeaveTM: Integrating Speed, Titer and Quality webinar
BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
Publication: Nature Communications